Scopus h-index:13
- Home
- Profiles
Video Visit Available
Accepting New Patients
Mount Sinai Doctors
Video Visit Available
Accepting New PatientsJoshua Richter, MD
Hematology-Oncology, Cancer (Oncology)
No Patient Experience Ratings
Ruttenberg Treatment Center
212-241-7873
- About Me
- Clinical Focus
- Education & Certifications
- Locations
- Insurance
- Publications
- Industry Relationships
About Me
Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood and the Journal of Clinical Oncology.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood and the Journal of Clinical Oncology.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood and the Journal of Clinical Oncology.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
Clinical Focus
- Amyloidosis
- Hematologic Malignancies
- Multiple Myeloma
- Amyloidosis
- Hematologic Malignancies
- Multiple Myeloma
Education
MD, New York Medical College
Internship, Internal Medicine
St. Vincent's Medical Center - New York Medical College
Residency, Internal Medicine
St. Vincent's Medical Center - New York Medical College
Fellowship, Hematology-Oncology
Yale Cancer Center
Certifications
American Board of Internal Medicine
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- AgeWell New York
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - Healthplus FKA Amerigroup Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare
- Metroplus
- Multiplan PHCS
- NY Medicaid
- Oxford - Freedom & Liberty
- Partners Health Plan
- Select Health Medicaid - VNSNY
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VillageCareMax
- WellCare Health Plan
- The Blavatnik Family - Chelsea Medical Center325 West 15th Street, 1st Floor, (between 8th and 9th Avenues), New York, NY, 10011
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- AgeWell New York
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - Healthplus FKA Amerigroup Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare
- Metroplus
- Multiplan PHCS
- NY Medicaid
- Oxford - Freedom & Liberty
- Partners Health Plan
- Select Health Medicaid - VNSNY
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Article:42
Review Article:18
Comment/Debate:1
Letter:6
Editorial:2
Recent Artifacts
- Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support
- Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
- MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
- MM-146 Using Data Science to Characterize Patterns in Cardiovascular Clinical Data: Topological Analysis of Baseline Characteristics in Patients With Relapsed/Refractory Multiple Myeloma Enrolled in Carfilzomib Trials
- MM-233 Evaluation of the Comparative Effectiveness of In-Class Transition (iCT) to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) After Bortezomib (V)-Based Induction Therapy vs Patients Who Continued to Receive Parenteral V-Based Therapy in Newly Diagnosed Multiple Myeloma (NDMM)
- MM-253 Efficacy, Safety, and Quality of Life (QoL) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) After In-Class Transition (iCT) From Parenteral Bortezomib-Based Induction Therapy to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd): Data From the Phase 4, Community-Based US MM-6 Study (Fully Accrued Cohort)
- MM-359 Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries With Newly Diagnosed Multiple Myeloma (NDMM) Treated With Bortezomib in Combination With Lenalidomide and Dexamethasone (VRd)
- What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma
- A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
- Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Richter during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- secura bio
- Bristol-Myers Squibb
- Janssen Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- sanofi-aventis
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Bristol-Myers Squibb
- Karyopharm Inc.
- oncopeptides
- adaptive biotechnologies
- sanofi-aventis
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- secura bio
- oncopeptides
- Celgene Corporation
- Amgen Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.